Charlotte Hubbert
Vice President of Corporate Strategy & DevelopmentDr. Charlotte Hubbert, Ph.D., is Vice President of Corporate Development of Lineage Cell Therapeutics, Inc. from April 2024 and serves its Vice President of Corporate Strategy since March 2026. Dr. Hubbert joined the Lineage Cell Therapeutics, Inc. in April 2024. Dr. Charlotte serves as Strategic Director at Madrona Venture Group, LLC since joining the firm on December 16, 2021. She serves as a Program Investment Officer in the program related investments team at The Bill & Melinda Gates Foundation. Dr. Hubbert serves as Director of Entrinsic Bioscience, Inc. (formerly known as Entrinsic Health Solutions, Inc.). since 2020. Dr. Hubbert served as a Vice President and Associate at H.I.G. BioVentures, LLC. Dr. Hubbert focused on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices. Prior to joining H.I.G. BioVentures, Dr. Hubbert served as an Associate at Accelerator Corporation and was responsible for identifying and evaluating emerging therapeutic technologies and supporting the executive team in financing and managing portfolio companies. She joined Accelerator Corporation in 2012. Dr. Hubbert's management responsibilities included support and strategic development of current portfolio companies, including direct interaction with Board of Directors, investors and partners. She has many years of life sciences experience, with proven performance in internationally recognized publications including Nature and Science. Dr. Hubbert serves as a Member of the Scientific Advisory Board at Oncofactor Corporation. Prior to joining Accelerator, she was a Ruth L. Kirschstein NIH post-doctoral fellow in stem cell and regenerative medicine at the University Washington. She serves as Director of Beckman Research Institute of City of Hope since September 2021. Dr. Hubbert was previously a partner and the head of Gates Foundation Venture Capital, an initiative at the Bill and Melinda Gates Foundation Strategic Investment Fund. In that role, she oversaw investing in innovative technologies that supported the Foundation’s programs in global health and agriculture. Her work focused on the immune response as an evolutionarily-differentiated system key to harnessing the regenerative power of inducible progenitor stem cells. She served as an Observer on the board of directors of Synlogic. She serves as an Observer on the board of directors of Sera Prognostics and Lodo Therapeutics. She serves as Hubbert is senior director of business development & strategic alliances at NanoString. She served as a Board observer at Cardeas Pharma and Alder Biopharmaceuticals. Dr. Hubbert did her Ph.D. in Pharmacology and Molecular Cancer Biology from Duke University from 1999 to 2005, as a fellow with the Department of Defense Breast Cancer Research Fund. In 2016, she was honored as Fierce Woman in Biopharma by FiercePharma and as a Leading Woman in Life Sciences by Life Science Washington. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Her Ph.D. work at Duke initiated a paradigm shift in the field of protein acetylation and for this work she was awarded the Harold M. Weintraub International Graduate Student Award for outstanding achievement from the Fred Hutchinson Cancer Research Center. Dr. Hubbert earned a B.S. in Microbiology from the University of Washington from 1995 to 1999.
Positions
- Company NameLineage Cell Therapeutics, Inc.Stock CodeLCTXPositionVice President of Corporate Strategy & DevelopmentColleagues
- BMBrian M. CulleyCEO, President & Director
- MHMichael H. MulroyIndependent Chairman
- JAJill Ann HoweChief Financial Officer
- GAGeorge A. SamuelGeneral Counsel & Company Secretary
- ICIoana C. HoneVP of Corporate Communications & Director of Investor Relations
- NCNeal Clifton BradsherIndependent Director
- DJDeborah J. AndrewsIndependent Director
- ACAngus C. RussellIndependent Director
